Swiss biotech startup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to support the commercial development of its platform, which helps drug developers identify immune-related risks earlier in the development process. By combining human immune tissue models with artificial intelligence, the company aims to improve the safety and success rate of next-generation biologic medicines.
Biologic drugs, including many therapeutic antibodies, can trigger unwanted immune responses that reduce treatment effectiveness, cause adverse side effects, and contribute to costly failures during clinical development. Current methods for predicting these responses often provide only limited insights, making it difficult for developers to detect potential risks before clinical trials.
ALP Bio addresses this challenge through a platform that combines human tonsil-derived immune models with AI-based protein modelling to predict how the immune system is likely to respond to therapeutic antibodies.
By generating insights based on human biology, the technology enables researchers to identify and mitigate immunogenicity risks at an earlier stage, supporting better drug design and increasing the likelihood of successful clinical outcomes.
Founded by Dr Christian Vahlensiek (CEO), Dr Lucas Schaus (CSO), Anatol Ehrlich (CTO), and Punit Mehra (CBO), ALP Bio brings together expertise in immunology, artificial intelligence, protein engineering, and business development.
The Venture Kick funding will support ALP Bio's first pilot projects with pharmaceutical partners. By co-financing these early collaborations, the company aims to validate its technology in real-world settings, facilitate its adoption, and strengthen its commercial position.
Would you like to write the first comment?
Login to post comments